
News|Articles|March 1, 2010
FDA Pipeline preview, March 2010 (CPI-300, Ondansetron, Intravenous acetaminophen, Gabapentin enacarbil, Rifaximin, ENMD-2076, Ap301, CM-AT, Fingolimod, Nilotinib)
Recent FDA action (through March 2010) related to CPI-300, Ondansetron, Intravenous acetaminophen, Gabapentin enacarbil, Rifaximin, ENMD-2076, Ap301, CM-AT, Fingolimod, Nilotinib.
Advertisement
Complete response
Recommendations for approval
Orphan drug designations
Priority review
Newsletter
Get the latest industry news, event updates, and more from Managed healthcare Executive.
Advertisement
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Transparency paves the way for lower costs and equitable access
2
New self-injectable biologics promise cost savings and patient convenience
3
Stanford scientists find link between Epstein-Barr virus and lupus
4
Evaluating Chronic Kidney Disease as a Risk Factor for Cardiovascular Disease: Written Recap
5






















































